pharmaceuticals

pharmaceuticals Articles

Shares of FibroGen saw a handy gain on Wednesday after the biopharmaceutical company announced the pricing of its underwritten follow-on offering.
Shanghai-based biopharmaceutical company Zai Lab has filed with the SEC regarding its initial public offering.
Zynerba Pharmaceuticals saw its shares sink to a 52-week low after the firm announced results from its midstage trial evaluating cannabidiol gel for the treatment of knee pain due to osteoarthritis.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
One in 12 U.S. doctors received more than $46 million from 2013 to 2015 in payments from drug companies that were selling strong painkillers, according to a new study.
Acadia Pharmaceuticals reported its second-quarter financial results after the markets closed on Tuesday.
Mylan released its most recent quarterly earnings report before the markets opened on Wednesday. Unfortunately, the earnings and guidance weren't strong enough to hold up the firm and as a result...
Valeant Pharmaceuticals reported mixed second-quarter financial results before the markets opened on Tuesday.
Horizon Pharma released a better than expected quarterly earnings report before the markets opened on Monday.
A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its approval of Imbruvica for the treatment of adult patients with chronic graft versus host disease.
Clementia Pharmaceuticals entered the market with a bang, with shares priced above expected price range.
Pharmaceuticals maker Pfizer reported second-quarter earnings before markets opened Tuesday, beating profit estimates by a penny a share, but coming up short on revenues.
No wonder there is a national problem with opioid use. A contributing factor has to be that almost 92 Americans used opioids in 2015.
Tetraphase Pharmaceuticals saw its shares pull back on Friday after the company announced that it has priced a secondary offering.
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.